Broad neutralization of SARS-CoV-2 variants, including omicron, following breakthrough infection with delta in COVID-19 vaccinated individuals

Cohort description

We identified 42 individuals admitted to St Thomas’ hospital who had previously received two COVID-19 vaccinations and subsequently tested positive for COVID-19. We note that at the time of writing, from the patients admitted to St Thomas’ Hospital with COVID-19 since the emergence of delta (n=635), 260 cases out of 332 (78%) where vaccination was known were either unvaccinated or partially vaccinated (one inoculation). In this study, 30/42 (71%) of patients in the BTI group were admitted to hospital due to COVID-19, of which 11/30 (37%) patients experienced severe disease (severity 4-5). 29/30 (97%) patients had underlying health conditions that predispose to severe disease and aged between 20-103 years (median age 77 years, IQR 59-86) (Table S1). The remaining 12 participants in the BTI group (29%) were asymptomatic and admitted for reasons other than COVID-19. Patients were aged between 24-96 years (median age 62 years, IQR 37-72). Overall, the BTI group included individuals receiving both the AZD1222 vaccine (n = 23) and the BNT162b2 vaccine (n = 19). Discarded serum samples were collected between 0-53 days post onset of symptoms (POS) and longitudinal serum samples were collected where possible. The number of days post second vaccine ranged from 29-179 days (median 109 days).

Sera (n = 19) were also collected from unvaccinated individuals admitted to St Thomas’ hospital due to COVID-19 who had a confirmed infection with the SARS-CoV-2 delta variant and experienced a range of disease severities with 9/19 (47%) patients experiencing severe disease (severity 4-5). Patients were aged between 25-82 years (median age 39 years, IQR 30-51) and 9/19 (47%) had underlying health conditions (Table S2). Sera were collected between 12-22 days POS.

IgG and IgM to Spike in breakthrough infection

First, we measured the IgG and IgM responses to recombinant Spike (both WT and delta) in the two groups by ELISA. Sera from unvaccinated individuals infected with the delta variant at 12-22 days POS had higher delta Spike IgM levels than delta Spike IgG (Figure 1A) indicative of a primary immune response. Slightly higher IgG and IgM titres were observed against the delta recombinant Spike compared to WT Spike (Figure 1B).

• Download figure
• Open in new tab

Figure 1: Differences in antibody binding between delta infected individuals and COVID-19 vaccinated individuals experiencing delta breakthrough infection.

A) Difference in IgG and IgM titres for sera collected 12-22 days POS for the delta infection (vaccine naïve) group. B) Comparison of the IgG and IgM ED₅₀ values against recombinant WT and delta Spikes for the vaccine naïve group. Black horizontal lines show the geometric mean titres. C) Difference in IgG and IgM titres for sera for the BTI group. D) Comparison of the IgG and IgM ED₅₀ values against recombinant WT and delta Spikes for the BTI group. Black horizontal lines show the geometric mean titres. E) Longitudinal IgG ED₅₀ against recombinant delta Spike in the BTI group. F) Longitudinal IgM ED₅₀ against recombinant delta Spike in the BTI group. Donors with IgM>IgG are shown in blue, donors who do not seroconvert are shown in red, donors with high Spike IgG but no N IgG at <7days POS are shown in orange, and donors with low Spike IgG at <7 days POS that rapidly increases are shown in yellow.

For sera collected 12-22 days POS in the BTI group, delta Spike IgM levels in the BTI group were lower than the delta Spike IgG level (Figure 1C) indicative of a recall response. A similar trend was observed for both AZD1222 and BNT162b2 vaccinated individuals (Figure S1A). Where sequential serum samples were collected, nine individuals had undetectable or a very low Spike IgG response at the earliest timepoint POS (Figure 1D and Figure S1B). However, high titres of Spike specific IgG were detected several days later with only modest increases in IgM titres (Figure 1E-F). Six donors had IgG against Spike at early time points but lacked IgG to the SARS-CoV-2 Nucleoprotein (Figure S1C-D). Although this may provide insight into Spike IgG levels prior to infection, it is more likely due to a rapid Spike IgG recall response compared to a de novo IgG response to Nucleoprotein (Figure 1E-F). One participant (a renal transplant patient) had a high IgM response and low IgG response, similar to the vaccine naïve group, which suggests failed vaccine priming (Figure 1C). Interestingly, unlike the vaccine naïve group, the IgG and IgM titres against the WT and delta Spikes were comparable in the BTI group (Figures 1D).

Overall, these results indicate a rapid recall response due to prior vaccination in the BTI group and a primary immune response in the vaccine naïve group.

Neutralization activity following breakthrough infection

Next, we measured neutralization breadth and potency in the two groups using HIV-1 (human immunodeficiency virus type-1) based virus particles, pseudotyped with SARS-CoV-2 Spike from different VOCs (wild-type (Wuhan), alpha (B.1.1.7), delta (B.1.617.2), mu (B.1.621) and beta (B.1.351)) and a HeLa cell-line stably expressing the ACE2 receptor (Seow et al., 2020). The majority (17/19, 89%) of the vaccine naïve group produced a robust homologous neutralizing response against the delta VOC (Figure 2A). Cross-neutralization of the parental strain and other VOCs was detected for most individuals, albeit at a reduced potency. As we have reported previously (Dupont et al., 2021), the greatest reduction was observed against beta with a 9.4-fold reduction in the GMT, reflecting greater antigenic distance.

• Download figure
• Open in new tab

Figure 2: Differences in neutralizing antibody response between delta infected individuals and COVID-19 vaccinated individuals experiencing delta breakthrough infection.

ID₅₀ of neutralization against WT (black) and VOCs alpha (blue), delta (purple), mu (red) and beta (orange) for sera from A) SARS-CoV-2 delta infected individuals and B) BTI individuals. Black line shows the geometric mean titre. Fold decrease in GMT compared to delta are shown above. Longitudinal neutralization potency of sera in BTI individuals against C) WT pseudovirus particles and D) delta pseudovirus particles. Donors with IgM>IgG are shown in blue, donors who do not seroconvert are shown in red, donors with high Spike IgG but no N IgG at <7days POS are shown in orange, and donors with low Spike IgG at <7 days POS that rapidly increases are shown in yellow. Data for the alpha, beta and mu VOCs is shown in Figure S2A. Correlation (Spearman, r) between ID₅₀ of neutralization and IgM or IgG ED₅₀ for delta Spike binding for E) delta infected individuals (IgM: r = 0.92, r² = 0.90, p <0.0001 and IgG: r = 0.66, r² = 0.43, p = 0.001) and F) COVID-19 vaccinated individuals experiencing breakthrough infection (IgM: r = 0.61, r² = 0.38, p <0.0001 and IgG: r = 0.83, r² = 0.75, p <0.0001). A linear regression was used to calculate the goodness of fit (r²). The dotted lines represent the lowest serum dilution used in each assay. IgG is shown with yellow circles and IgM shown with red circles.

Sera collected between 12-22 days POS from individuals in the BTI group showed a robust homologous neutralizing response as well as strong cross-neutralization of the parental variant and VOCs (Figure 2B). Only a 1.2-fold reduction in GMT was observed against the more neutralization resistant beta VOC. Several individuals in the BTI group with sera collected soon after onset of symptoms showed no or very low neutralization against both WT and delta variants, however, potent neutralizing activity was detected several days later (Figure 2C&D and S2A). Geometric mean titres against the five variants were very similar between AZD1222 and BNT162b2 vaccinated individuals (Figure S2B). Three participants in the BTI group either failed to produce neutralizing antibodies or had titres close to baseline despite vaccination and SARS-CoV-2 infection. These individuals had underlying health conditions including cancer (one participant was undergoing rituximab treatment) and type-2 diabetes.

As would have been anticipated, IgG ED₅₀ values correlated best with ID₅₀ values for the BTI group whereas IgM ED₅₀ values correlated best with ID₅₀ values for the unvaccinated group (Figure 2E&F) further highlighting the priming capacity of both the AZ and BNT162b2 vaccines.

BTI generates neutralizing activity against omicron

In November 2021, omicron (B.1.1.529) was identified that encoded 31 amino acid mutations in the Spike protein (Figure 3A). Initial studies suggest that these mutations lead to large reductions in neutralization of sera from double vaccinated individuals. However, administration of a third vaccine dose greatly enhances neutralization titres against omicron suggesting incomplete neutralization escape (Cameroni, 2021; Cele et al., 2021; Doria-Rose, 2021; Garcia-Beltran, 2021; Gruell, 2021; Schmidt, 2021). Neutralization activity of a subset of 14 sera from the vaccine naïve group and 15 sera from the BTI group were measured against WT, delta and omicron variants (Figure 3B&D). In delta infected individuals, a 28.9-fold reduction in GMT against omicron compared to delta was measured compared to a 6.9-fold reduction in GMT for WT. Sera from two participants did not neutralize the omicron variant at the lowest dilution point (1:25). In contrast, all 15 sera from the BTI group neutralized the omicron variant with only a 4.5-fold reduction in GMT against omicron compared to delta GMT (Figure 3C&E). Three individuals showed a 21-to 81-fold reduction in ID₅₀ against omicron compared to ID₅₀ against delta, all of which were receiving treatment for underlying health conditions. These results further highlight the breadth of the neutralizing antibody response following BTI with the delta variant.

• Download figure
• Open in new tab

Figure 3: Neutralization of omicron in BTI and delta infected individuals.

A) Schematic showing mutations in the delta (B.1.617.2) and omicron (B.1.1.529) Spikes. Select sera from B) SARS-CoV-2 delta infected (vaccine naïve) individuals (13-22 days POS) and C) BTI individuals (12-21 days POS) was tested against WT, delta and omicron VOCs. ID₅₀ of neutralization against WT (black) and VOCs delta (purple), and omicron (turquoise) for each participant are linked. Geometric mean titres against WT, delta and omicron VOCs for D) SARS-CoV-2 delta infected individuals (13-22 days POS) and E) BTI individuals (12-21 days POS). Black line shows the geometric mean titre. Fold decrease in GMT against omicron compared to WT and delta are shown above.

Ethics

Collection of surplus serum samples was approved by South Central – Hampshire B REC (20/SC/0310). SARS-CoV-2 cases were diagnosed by RT–PCR of respiratory samples at St Thomas’ Hospital, London. Sera were selected on the availability of longitudinal samples and knowledge of timing and type of COVID-19 vaccination.

COVID-19 severity classification

Disease severity was determined as previously described (Dupont et al., 2021; Seow et al., 2020). Patients diagnosed with COVID-19 were classified as follows: (0) Asymptomatic or no requirement for supplemental oxygen; (1) Requirement for supplemental oxygen (fraction of inspired oxygen (FiO2) < 0.4) for at least 12 h; (2) Requirement for supplemental oxygen (FiO2 ≥ 0.4) for at least 12 h; (3) Requirement for non-invasive ventilation/continuous positive airway not a candidate for escalation above level one (ward-based) care; (4) Requirement for intubation and mechanical ventilation or supplemental oxygen (FiO2 > 0.8) and peripheral oxygen saturations <90% (with no history of type 2 respiratory failure (T2RF)) or <85% (with known T2RF) for at least 12 h; (5) Requirement for ECMO.

Virus sequencing

Delta variant infection was confirmed using whole genome sequencing as previously described (Dupont et al., 2021) or using MT-PCR (Hale et al., 2021).

Plasmids

WT, B.1.1.7, B.1.351, B.1.621, B.1.617.2 and B.1.1.529 codon optimized Spike plasmids were obtained from Wendy Barclay (Imperial College London). The final 19 amino acids were removed using an K1255* mutation. B.1.1.7 mutations introduced were ΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H. B.1.351 mutations introduced were D80A, D215G, Delta242-244, R246I, K417N, E484K, N501Y, D614G, A701V. B.1.617.2 mutations introduced were: T19R, G142D, Δ156-157, R158G, L452R, T478R, D614G, P681R, D950N. B.1.621 mutations introduced were: T95I, Y144T/144insS/Y145N, R346K, E484K, N501Y, D614G, P681H, D950N. B.1.1.529 mutations introduced were: A67V, Δ69-70, T95I, G142D/Δ143-145, Δ211/L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F.

Glycoprotein expression and purification

The recombinant wild-type (Wuhan-1 strain) and delta (B.1.617.2) consist of a pre-fusion S ectodomain residues 1–1138 with proline substitutions at amino acid positions 986 and 987, a GGGG substitution at the furin cleavage site (amino acids 682–685) and an N terminal T4 trimerisation domain followed by a Strep-tag II (Brouwer et al., 2020). Spike was expressed in HEK 293 Freestyle cells and purified using StrepTactinXT Superflow high capacity 50% suspension according to the manufacturer’s protocol by gravity flow (IBA Life Sciences).

N protein was obtained from the James lab at LMB, Cambridge. The N protein is a truncated construct of the SARS-CoV-2 N protein comprising residues 48–365 with an N terminal uncleavable hexahistidine tag. N was expressed in E. Coli using autoinducing media for 7h at 37 °C and purified using immobilised metal affinity chromatography (IMAC), size exclusion and heparin chromatography.

Spike IgG titres by ELISA

ELISA was carried out as previously described (Seow et al., 2020). All sera were heat-inactivated at 56°C for 30 mins before use in the in-house ELISA. High-binding ELISA plates (Corning, 3690) were coated with antigen (N or Spike (WT or delta)) at 3 µg/mL (25 µL per well) in PBS overnight at 4°C. Wells were washed with PBS-T (PBS with 0.05% Tween-20) and then blocked with 100 µL 5% milk in PBS-T for 1 hr at room temperature. Wells were emptied and a titration of serum starting at 1:50 and using a 6-fold dilution series in milk was added and incubated for 2 hr at room temperature. Control reagents included CR3009 (2 µg/mL), CR3022 (0.2 µg/mL), negative control plasma (1:25 dilution), positive control plasma (1:50) and blank wells. Wells were washed with PBS-T. Secondary antibody was added and incubated for 1 hr at room temperature. IgM was detected using Goat-anti-human-IgM-HRP (horseradish peroxidase) (1:1,000) (Sigma: A6907) and IgG was detected using Goat-anti-human-Fc-AP (alkaline phosphatase) (1:1,000) (Jackson: 109-055-098). Wells were washed with PBS-T and either AP substrate (Sigma) was added and read at 405 nm (AP) or 1-step TMB (3,3′,5,5′-Tetramethylbenzidine) substrate (Thermo Scientific) was added and quenched with 0.5 M H₂S0₄ before reading at 450 nm (HRP). Half-maximal binding (EC₅₀) was calculated using GraphPad Prism. Measurements were carried out in duplicate.

SARS-CoV-2 pseudotyped virus particle preparation

Pseudotyped HIV-1 virus incorporating the SARS-CoV-2 Spike protein (either wild-type, B.1.1.7, B.1.351, B.1 621, B.1.617.2 or B.1.1.529) were prepared as previously described (Dupont et al., 2021). Viral particles were produced in a 10 cm dish seeded the day prior with 5×10⁶ HEK293T/17 cells in 10 ml of complete Dulbecco’s Modified Eagle’s Medium (DMEM-C, 10% FBS and 1% Pen/Strep) containing 10% (vol/vol) foetal bovine serum (FBS), 100 IU/ml penicillin and 100 μg/ml streptomycin. Cells were transfected using 90 μg of PEI-Max (1 mg/mL, Polysciences) with: 15μg of HIV-luciferase plasmid, 10 μg of HIV 8.91 gag/pol plasmid and 5 μg of SARS-CoV-2 spike protein plasmid.(Grehan et al., 2015; Thompson et al., 2020) The supernatant was harvested 72 hours post-transfection. Pseudotyped virus particles was filtered through a 0.45μm filter, and stored at -80°C until required.

Neutralization assay with SARS-CoV-2 pseudotyped virus

Serial dilutions of serum samples (heat inactivated at 56°C for 30mins) were prepared with DMEM media (25µL) (10% FBS and 1% Pen/Strep) and incubated with pseudotyped virus (25µL) for 1-hour at 37°C in half-area 96-well plates. Next, Hela cells stably expressing the ACE2 receptor were added (10,000 cells/25µL per well) and the plates were left for 72 hours. Infection levels were assessed in lysed cells with the Bright-Glo luciferase kit (Promega), using a Victor™ X3 multilabel reader (Perkin Elmer). Each serum sample was run in duplicate and was measured against the five SARS-CoV-2 variants within the same experiment using the same dilution series.

Statistical analysis

Analyses were performed using GraphPad Prism v.8.3.1.